Classic homocystinuria is a hereditary disorder characterized by a defect in the enzyme cystathionine beta-synthase (CBS), which catalyzes the conversion of homocysteine to cystathionine in the transsulfuration pathway. The resulting enzymatic deficiency leads to systemic accumulation of homocysteine, a sulfur-containing amino acid that can exert toxic effects through oxidative stress and endothelial dysfunction. Elevated homocysteine levels are associated with a spectrum of clinical manifestations including thromboembolism, ocular abnormalities, skeletal deformities, and cognitive impairment. Furthermore, aberrant methionine metabolism contributes to secondary metabolic disturbances with hepatic repercussions.

Choline, an essential nutrient classified alongside B vitamins, plays a pivotal role as a methyl-group donor through its conversion to betaine, thereby supporting the remethylation of homocysteine to methionine. Additionally, choline is integral to the synthesis of phosphatidylcholine, a major component of very low-density lipoproteins (VLDL), crucial for hepatic lipid export. The interplay between choline availability, homocysteine accumulation, and lipid metabolism forms the biochemical basis for investigating choline supplementation as a therapeutic strategy in homocystinuria.

The correction put forth by Kahraman et al. addresses previous discrepancies related to the extent of choline’s impact on homocysteine concentrations and the development of hepatic steatosis within their patient cohort. Through rigorous reanalysis and refined methodological approaches, the authors clarify that choline supplementation leads to a statistically significant reduction in plasma homocysteine levels in individuals with classic homocystinuria. This outcome substantiates the methyl donor role of choline and its efficacy in modulating one-carbon metabolism, which is critically compromised in CBS deficiency.

Importantly, the study also revises earlier interpretations concerning hepatic steatosis—a pathological accumulation of triglycerides in hepatocytes frequently linked to metabolic dysfunction. Prior observations suggested that intrinsic homocysteine elevation might directly exacerbate steatosis through oxidative and inflammatory mechanisms. However, the correction elucidates that choline supplementation ameliorates hepatic steatosis, likely by enhancing VLDL synthesis and secretion, thereby mitigating hepatic lipid retention. This highlights choline’s multifaceted functionality extending beyond simple homocysteine detoxification towards correcting lipid metabolic derangements.

From a molecular perspective, choline’s impact on hepatic health is mediated through complex interlinked pathways involving the methionine cycle, folate metabolism, and phospholipid biosynthesis. The correction underscores the balance required in methylation reactions; inadequate methyl donor availability impairs remethylation of homocysteine, exacerbating hyperhomocysteinemia and associated cytotoxicity. Concurrently, insufficient phosphatidylcholine compromises hepatocellular lipid export, precipitating fatty infiltration. By restoring these processes, choline supplementation addresses the metabolic bottlenecks inherent in classic homocystinuria at multiple biochemical nodes.

Clinically, these findings warrant careful consideration in dietary management and pharmacological interventions for homocystinuria patients. Standard treatments conventionally focus on vitamin B6 supplementation and betaine therapy to lower homocysteine. The revelation that choline supplementation independently contributes to homocysteine reduction and hepatic protection opens avenues for integrated nutritional strategies. Personalized choline dosing regimens could optimize metabolic control and prevent liver-related complications, improving patient prognosis.

Moreover, the corrected data provoke broader reflections on the role of choline in nonalcoholic fatty liver disease (NAFLD) and other hepatic disorders characterized by disrupted methylation and lipid metabolism. Given the mounting prevalence of NAFLD worldwide, insights derived from the rare context of homocystinuria might offer translational value. This study prompts intensified research into choline’s therapeutic potential for mitigating steatosis across diverse metabolic contexts.

The interplay between homocysteine and hepatic lipid accumulation is complex and bidirectional. Elevated homocysteine induces oxidative stress, triggers ER stress pathways, and modulates inflammatory cascades that aggravate liver injury. Conversely, hepatic steatosis influences methionine metabolism and methyl donor dynamics, further perturbing homocysteine homeostasis. By demonstrating that choline supplementation alleviates both hyperhomocysteinemia and steatosis, the correction clarifies an interventional target that coordinates multiple pathological axes.

Future research based on these findings could examine choline supplementation dosage, timing, and long-term safety in homocystinuria patients. Additionally, integration with other methyl donors such as folate and vitamin B12 could be studied to identify synergistic effects on metabolic parameters. Given the genetic heterogeneity of homocystinuria and variable CBS enzyme activity, stratified clinical trials assessing genotype-phenotype-specific responses are warranted.

This correction also calls attention to the importance of rigorous data validation and transparency in rare disease research. The meticulous reevaluation by Kahraman and colleagues exemplifies scientific integrity and advances collective understanding, ensuring that clinical recommendations are grounded in robust evidence. As metabolic pathways often intersect with broader physiological systems, even subtle biochemical modulations can have profound implications for patient care.

Technological advances in metabolomics, transcriptomics, and imaging could deepen insights into choline’s mechanistic roles in homocystinuria and related metabolic disorders. High-resolution lipid profiling and quantification of methylation intermediates could refine biomarkers of therapeutic response. Additionally, liver biopsy analyses complemented by non-invasive imaging would better characterize steatosis progression and resolution patterns under choline therapy.

In conclusion, this correction underscores choline supplementation as a promising adjunct in managing classic homocystinuria. By significantly diminishing plasma homocysteine levels and reversing hepatic steatosis, choline concurrently targets metabolic imbalances and organ-specific pathology. These findings enhance the therapeutic landscape for this rare but severe condition and inspire wider exploration of nutrient-based interventions in complex metabolic diseases.

As homocystinuria exemplifies the intricate crosstalk between genetics, metabolism, and organ health, interventions like choline supplementation embody the future of precision medicine. Continuing efforts to unravel molecular intricacies while validating clinical outcomes will pave the way for optimized multidisciplinary care. This research correction by Kahraman et al. not only enriches our scientific understanding but may also improve quality of life for patients grappling with challenging metabolic disorders.

Subject of Research: Choline supplementation effects on homocysteine metabolism and hepatic steatosis in classic homocystinuria.

Article Title: Correction: Choline supplementation in classic homocystinuria: impact on homocysteine and hepatic steatosis.

Article References:
Kahraman, S., Gedikbasi, A., Karaca, M. et al. Correction: Choline supplementation in classic homocystinuria: impact on homocysteine and hepatic steatosis. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04549-1

Image Credits: AI Generated

In a groundbreaking study recently published in Pediatric Research, Kahraman and colleagues delve into the potential role of choline supplementation in managing elevated homocysteine levels among CBS-deficient homocystinuria patients. The team focused particularly on patients who, despite receiving conventional treatment regimens, persistently exhibited hyperhomocysteinemia. This work not only broadens the understanding of choline’s biochemical interactions but also raises the prospect of novel adjunctive therapies that could improve patient outcomes beyond current standards.

Choline, an essential nutrient pivotal for one-carbon metabolism and methyl group donation, bears a profound influence on hepatic lipid processing and homocysteine remethylation. The enzyme CBS’s deficiency disorganizes sulfur amino acid pathways, culminating in metabolic bottlenecks that may be partially alleviated through enhanced methyl group availability. By integrating choline supplementation, the researchers hypothesized that homocysteine levels could be modulated indirectly, mitigating both toxic plasma accumulation and downstream hepatic complications.

The investigative team employed rigorous biochemical assays to ascertain the baseline choline status in classic homocystinuria patients, identifying a pattern of relative insufficiency compared to healthy controls. This finding illuminates a potentially overlooked aspect of metabolic derangement in CBS deficiency—nutrient imbalances that could exacerbate canonical symptoms. The data suggest that deficient choline availability might intensify homocysteine accumulation via impaired methylation cycles, further complicating disease pathogenesis.

Therapeutic intervention involved administering controlled doses of choline supplementation alongside standard treatments, including vitamin B6, folate, and betaine. Over the intervention period, researchers meticulously monitored plasma homocysteine concentrations, liver function markers, and imaging-based assessments of hepatic steatosis. The results demonstrated a statistically significant decline in homocysteine levels among supplemented subjects, suggesting a synergistic role of choline with conventional therapies.

Importantly, the study also revealed a concurrent improvement in hepatic steatosis parameters, a common but underexplored comorbidity in homocystinuria. The correlation between elevated plasma homocysteine and lipid accumulation in hepatocytes underscores a pathological link that choline might alleviate by enhancing hepatic lipid metabolism and reducing oxidative stress. These findings hint at an expanded therapeutic window for tackling liver manifestations in CBS deficiency beyond homocysteine normalization.

The mechanistic underpinnings relate to choline’s role as a precursor to phosphatidylcholine, essential for very-low-density lipoprotein (VLDL) assembly and secretion. Impaired VLDL formation can lead to intracellular lipid retention, precipitating hepatic steatosis. By supplementing choline, normal lipid export pathways may be restored, preventing hepatocellular lipid overload. This mechanism intricately connects choline metabolism with homocysteine’s toxic effects, delineating an interwoven metabolic network influenced by CBS activity.

From a broader perspective, the study’s revelations may catalyze a paradigm shift in how clinicians approach the treatment of classic homocystinuria. Rather than solely targeting homocysteine reduction, integrated management strategies that restore metabolic equilibrium encompassing choline and related nutrient pathways could emerge. This holistic view aligns with contemporary precision medicine trends emphasizing individualized biochemical profiling and targeted supplementation.

Moreover, these findings could inspire research into other metabolic diseases characterized by disrupted sulfur amino acid metabolism or methylation cycles. Given choline’s ubiquitous role in cellular biochemistry, its supplementation might prove beneficial in diverse contexts where methyl donor deficits exacerbate disease phenotypes. The crosstalk between choline metabolism and homocysteine regulation could thus become a focal point for novel therapeutic development.

Despite the promising outcomes, the study acknowledges several limitations, including the relatively small cohort size and short duration of choline supplementation. Longitudinal studies with larger populations are necessary to validate the durability of treatment effects and uncover potential long-term adverse outcomes. Additionally, clarifying optimal dosing regimens and potential interactions with other vitamins integral to one-carbon metabolism remains an imperative for clinical translation.

Critically, the safety profile of choline supplementation in pediatric populations must be thoroughly characterized. While choline is deemed generally safe at recommended daily intakes, high doses could theoretically provoke side effects or interact unfavorably with existing medications. The study’s adherence to carefully titrated supplementation protocols sets an important precedent for future interventions.

The integration of advanced imaging modalities to quantify hepatic steatosis represents another strength of this research. By correlating biochemical markers with direct visualization of liver tissue characteristics, the authors provide robust evidence linking metabolic correction to tangible organ-level improvements. This multimodal approach strengthens the causal inference between choline supplementation and amelioration of hepatic pathology.

For the field of pediatric metabolic disorders, this study signals an exciting advance. Classic homocystinuria patients, who often endure lifelong morbidity, may benefit from new adjunctive therapies that go beyond symptom management toward metabolic restoration. The evidence supporting choline supplementation invites renewed exploration into dietary and pharmacological strategies that harness nutrient metabolism for disease modification.

Future research trajectories inspired by these findings could explore combinatorial interventions engaging multiple metabolic pathways simultaneously. For instance, integrating choline with other emerging agents targeting sulfur amino acid cycles might produce synergistic benefits. Furthermore, genetic and epigenetic profiling may identify patient subgroups most likely to respond favorably to such tailored interventions.

In sum, the elucidation of choline’s impact on homocysteine regulation and hepatic steatosis in CBS-deficient classic homocystinuria patients offers a new frontier for metabolic disease treatment. This research underscores the importance of considering broader nutrient interactions within disease pathogenesis and therapeutic design. As metabolic medicine continues to evolve, such insights broaden the horizon of possibilities for patients who have long awaited more effective solutions.

Subject of Research: Classic homocystinuria and the impact of choline supplementation on plasma homocysteine levels and hepatic steatosis in CBS-deficient patients.

Article Title: Choline supplementation in classic homocystinuria: impact on homocysteine and hepatic steatosis.

Article References:
Kahraman, S., Gedikbasi, A., Karaca, M. et al. Choline supplementation in classic homocystinuria: impact on homocysteine and hepatic steatosis. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04383-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04383-5